v3.25.4

SEGMENT INFORMATION | 12 Months Ended
--- | ---
Dec. 31, 2025
Segment Reporting [Abstract] |
SEGMENT INFORMATION | SEGMENT INFORMATION Reportable Segments The Company’s Chief Executive Officer, who is the Company’s Chief Operating Decision Maker, manages the business through three operating segments, consistent with how the Company’s Chief Executive Officer: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following operating segments, which also qualify as reportable segments: (i) Vision Care, (ii) Pharmaceuticals and (iii) Surgical. These segments are generally determined based on the decision-making structure of Bausch + Lomb and the grouping of similar products and services. •The Vision Care segment consists of: (i) sales of contact lenses that span the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses, and (ii) sales of contact lens care products, OTC eye drops that address various conditions, including eye allergies, conjunctivitis, dry eye and redness relief, and eye vitamin and mineral supplements. •The Pharmaceuticals segment consists of sales of a broad line of proprietary and generic pharmaceutical products for post-operative treatments and the treatment of a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. •The Surgical segment consists of sales of medical device equipment, consumables and technologies for the treatment of cataracts, corneal, vitreous and retinal eye conditions, which includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s Chief Operating Decision Maker uses segment profit to assess operating performance and make resource allocation decisions for each of its segments. Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of Bausch + Lomb’s businesses and incurs certain expenses, gains and losses related to the overall management of Bausch + Lomb, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment. Segment Revenues and Profit Segment revenues and profits for the years 2025, 2024 and 2023 were as follows:
| Vision Care |  | Pharmaceuticals |  | Surgical |  | Total
(in millions) | 2025 |  | 2024 |  | 2023 |  | 2025 |  | 2024 |  | 2023 |  | 2025 |  | 2024 |  | 2023 |  | 2025 |  | 2024 |  | 2023
Revenues |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Product Sales | $ | 2,914 |  |  | $ | 2,731 |  |  | $ | 2,535 |  |  | $ | 1,277 |  |  | $ | 1,206 |  |  | $ | 834 |  |  | $ | 889 |  |  | $ | 837 |  |  | $ | 762 |  |  | $ | 5,080 |  |  | $ | 4,774 |  |  | $ | 4,131 |
Other Revenues | 9 |  |  | 8 |  |  | 8 |  |  | 7 |  |  | 3 |  |  | 2 |  |  | 5 |  |  | 6 |  |  | 5 |  |  | 21 |  |  | 17 |  |  | 15 |
| 2,923 |  |  | 2,739 |  |  | 2,543 |  |  | 1,284 |  |  | 1,209 |  |  | 836 |  |  | 894 |  |  | 843 |  |  | 767 |  |  | 5,101 |  |  | 4,791 |  |  | 4,146 |
Expenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of goods sold (excluding amortization and impairments of intangible assets) | 1,113 |  |  | 1,002 |  |  | 954 |  |  | 397 |  |  | 374 |  |  | 252 |  |  | 535 |  |  | 492 |  |  | 434 |  |  |  |  |  |  |
Cost of other revenues | 1 |  |  | 1 |  |  | 1 |  |  | 4 |  |  | 3 |  |  | 1 |  |  | — |  |  | — |  |  | — |  |  |  |  |  |  |
Selling, general and administrative | 912 |  |  | 882 |  |  | 832 |  |  | 572 |  |  | 543 |  |  | 322 |  |  | 298 |  |  | 265 |  |  | 248 |  |  |  |  |  |  |
Research and development | 48 |  |  | 46 |  |  | 67 |  |  | 53 |  |  | 33 |  |  | 20 |  |  | 43 |  |  | 42 |  |  | 35 |  |  |  |  |  |  |
Segment Profit | $ | 849 |  |  | $ | 808 |  |  | $ | 689 |  |  | $ | 258 |  |  | $ | 256 |  |  | $ | 241 |  |  | $ | 18 |  |  | $ | 44 |  |  | $ | 50 |  |  | 1,125 |  |  | 1,108 |  |  | 980 |
Corporate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (679) |  |  | (614) |  |  | (536) |
Amortization of intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (258) |  |  | (288) |  |  | (240) |
Other expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (75) |  |  | (44) |  |  | (74) |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 113 |  |  | 162 |  |  | 130 |
Interest income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 |  |  | 15 |  |  | 15 |
Interest expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (421) |  |  | (399) |  |  | (283) |
Loss on extinguishment of debt |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (6) |  |  | — |  |  | — |
Foreign exchange and other |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (15) |  |  | (12) |  |  | (28) |
Loss before provision for income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | (317) |  |  | $ | (234) |  |  | $ | (166) |
Revenues by Segment and by Product Category Revenues by segment and product category were as follows:
| Vision Care |  | Pharmaceuticals |  | Surgical |  | Total
(in millions) | 2025 |  | 2024 |  | 2023 |  | 2025 |  | 2024 |  | 2023 |  | 2025 |  | 2024 |  | 2023 |  | 2025 |  | 2024 |  | 2023
Pharmaceuticals | $ | 5 |  |  | $ | 4 |  |  | $ | 4 |  |  | $ | 1,076 |  |  | $ | 965 |  |  | $ | 614 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 1,081 |  |  | $ | 969 |  |  | $ | 618 |
Devices | 1,033 |  |  | 963 |  |  | 888 |  |  | — |  |  | — |  |  | — |  |  | 889 |  |  | 837 |  |  | 762 |  |  | 1,922 |  |  | 1,800 |  |  | 1,650 |
OTC | 1,834 |  |  | 1,724 |  |  | 1,611 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 1,834 |  |  | 1,724 |  |  | 1,611 |
Branded and Other Generics | 42 |  |  | 40 |  |  | 32 |  |  | 201 |  |  | 241 |  |  | 220 |  |  | — |  |  | — |  |  | — |  |  | 243 |  |  | 281 |  |  | 252 |
Other revenues | 9 |  |  | 8 |  |  | 8 |  |  | 7 |  |  | 3 |  |  | 2 |  |  | 5 |  |  | 6 |  |  | 5 |  |  | 21 |  |  | 17 |  |  | 15 |
| $ | 2,923 |  |  | $ | 2,739 |  |  | $ | 2,543 |  |  | $ | 1,284 |  |  | $ | 1,209 |  |  | $ | 836 |  |  | $ | 894 |  |  | $ | 843 |  |  | $ | 767 |  |  | $ | 5,101 |  |  | $ | 4,791 |  |  | $ | 4,146 |
The top ten products/franchises represented 56%, 54% and 48% of total revenues for the years 2025, 2024 and 2023, respectively. Geographic Information Revenues are attributed to a geographic region based on the location of the customer for the years 2025, 2024 and 2023 and were as follows:
(in millions) | 2025 |  | 2024 |  | 2023
U.S. and Puerto Rico | $ | 2,546 |  |  | $ | 2,413 |  |  | $ | 1,934 |
China | 358 |  |  | 358 |  |  | 344 |
France | 246 |  |  | 227 |  |  | 210 |
Japan | 186 |  |  | 180 |  |  | 187 |
Germany | 164 |  |  | 152 |  |  | 147 |
Russia | 148 |  |  | 120 |  |  | 106 |
United Kingdom | 137 |  |  | 132 |  |  | 121 |
Canada | 135 |  |  | 127 |  |  | 110 |
Italy | 102 |  |  | 91 |  |  | 82 |
Spain | 101 |  |  | 92 |  |  | 85 |
Mexico | 75 |  |  | 75 |  |  | 68 |
Poland | 75 |  |  | 65 |  |  | 51 |
South Korea | 51 |  |  | 47 |  |  | 46 |
Other | 777 |  |  | 712 |  |  | 655 |
| $ | 5,101 |  |  | $ | 4,791 |  |  | $ | 4,146 |
Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December 31, 2025 and 2024 and were as follows:
(in millions) | 2025 |  | 2024
U.S. and Puerto Rico | $ | 836 |  |  | $ | 798 |
Ireland | 544 |  |  | 424 |
Germany | 162 |  |  | 104 |
Other | 220 |  |  | 159 |
| $ | 1,762 |  |  | $ | 1,485 |
Major Customers Major customers that accounted for approximately 10% or more of total revenues were as follows:
| 2025 |  | 2024 |  |  |  |
McKesson Corporation | 10 | % |  | 10 | % |  |  |  |
Cardinal Health, Inc. | 10 | % |  | 10 | % |  |  |  |
For the year 2023, no individual customer accounted for approximately 10% or more of total revenues.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration